iBio (NASDAQ:IBIO), an AI-driven pioneer in antibody discovery and development, announced on April 8, 2026, that it has received the necessary regulatory clearances to begin its Phase 1 clinical trial of IBIO-600, a novel candidate for the treatment of obesity.
The company received Clinical Trial Notification (CTN) acknowledgement from Australia’s Therapeutic Goods Administration (TGA) and approval from the Human Research Ethics Committee (HREC).
The randomized, double-blind, placebo-controlled study is a single ascending dose (SAD) trial that will evaluate the safety, tolerability, and pharmacokinetics of IBIO-600 in overweight and obese adults.
IBIO-600 distinguishes itself in the crowded weight-loss market by targeting myostatin and GDF11.
While many existing GLP-1 therapies result in significant muscle loss alongside fat reduction, IBIO-600 is engineered to preserve—and potentially increase—lean mass.
In preclinical non-human primate studies, the candidate showed lean-mass gains of 4.1% to 5.1% while simultaneously driving fat-mass reductions.
A key competitive advantage of IBIO-600 is its extended half-life, which was observed to be between 40 and 52 days in preclinical models.
This profile supports a highly convenient, infrequent dosing schedule, potentially requiring only two to four administrations per year.
This contrasts sharply with the weekly injection schedules required by current market leaders.
First participant dosing in the Australian Phase 1 trial is expected to occur in the second quarter of 2026.
The study will provide the first human data on whether the impressive lean-mass preservation seen in animal models translates to clinical settings.